Boston Scientific (NYSE:BSX) Releases FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 2.870-2.940 for the period, compared to the consensus EPS estimate of 2.880. The company issued revenue guidance of $19.3 billion-$19.6 billion, compared to the consensus revenue estimate of $19.5 billion. Boston Scientific also updated its Q2 2025 guidance to 0.710-0.730 EPS.

Boston Scientific Trading Up 0.0%

Shares of BSX stock opened at $99.38 on Thursday. The firm has a 50 day moving average price of $100.70 and a two-hundred day moving average price of $98.55. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $147.03 billion, a PE ratio of 79.50, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific has a 12-month low of $71.88 and a 12-month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period last year, the business posted $0.56 earnings per share. As a group, analysts predict that Boston Scientific will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BSX shares. Morgan Stanley raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, May 16th. Barclays raised their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, April 25th. Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. Evercore ISI raised their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an “outperform” rating in a report on Thursday, April 24th. Finally, Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, April 29th. Twenty-one investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $116.00.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,314 shares of Boston Scientific stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president now owns 22,235 shares in the company, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president now owns 178,342 shares in the company, valued at approximately $18,347,824.96. This trade represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC boosted its position in Boston Scientific Co. (NYSE:BSX) by 0.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,376 shares of the medical equipment provider’s stock after buying an additional 226 shares during the period. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 at the end of the most recent quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.